Dr. Rahul Aras, CEO of Iterion Therapeutics, a clinical stage biotechnology company developing novel cancer therapeutics discusses the company’s lead product, Tegavivint, a unique nuclear β-catenin inhibitor, which is currently advancing to a Phase 2 clinical trial in patients with progressive desmoid tumors. The company will also pursue additional clinical programs in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers this year and in 2021.
Dr. Aras joined Iterion as President and CEO in June 2018, bringing more than 15 years of experience in the biotechnology industry, including all aspects of raising funding, product development, business development and executive management. Prior to Iterion, he served as founding President & CEO of Juventas Therapeutics, where he successfully advanced their gene therapy platform from concept into mid-stage clinical trials and a partnership with a leading global pharmaceutical company. In addition, he has worked with several start-up biotechnology companies to accelerate growth through product proof of concept and value creation. He has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University.